by: Brigid Schulte
Orginally published in Washington Post
The Food and Drug Administration said that safety concerns outweighed any benefits, and, in 2013, again rejected the drug for approval.The manufacturer, Sprout Pharmaceuticals resubmitted an application for approval in February with additional safety studies. And on Thursday, an advisory committee of the FDA will again examine the risks and rewards of the drug. Their vote could influence the final FDA decision, due in August.
Read the full article